Clinical trials: Obstructive Pulmonary Disease
Asthma
Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma
The purpose of the study is to find out if taking vitamin D in addition to an asthma controller medication helps to prevent worsening of asthma symptoms and asthma attacks.
- Trial name
- VIDA (NCT01248065)
- Testing
- Vitamin D3, Ciclesonide
- Where
- 16 sites in United States
- Volunteers
- 408 people
- Sponsor
- Milton S. Hershey Medical Center
Pulmonary Disease, Chronic Obstructive
Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto® Respimat® (AERIAL®)
The objective of this NIS is to measure changes in health status including functional status using CCQ scores in COPD patients receiving treatment with Spiolto® Respimat® according to label after approximately 6 weeks in routine…
- Trial name
- NCT03165045
- Testing
- Spiolto® Respimat®
- Where
- 108 sites in Germany
- Volunteers
- 1,351 people
- Sponsor
- Boehringer Ingelheim
Asthma, Acute Asthma
Budesonide Inhalation Suspension for Acute Asthma in Children
The purpose of this study is to determine whether the addition of budesonide inhalation suspension (BIS) to the standard therapy of albuterol, ipratropium bromide, and systemic corticosteroids (SCS) for moderate to severe asthma…
- Conditions
- Asthma, Acute Asthma, Reactive Airway Exacerbation
- Trial name
- NCT00393367
- Testing
- Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg, Prednisolone, prednisone, or methylprednisolone, Albuterol, ipratropium bromide
- Where
- United States
- Volunteers
- 179 people
- Sponsor
- Children's Hospital of Philadelphia
Asthma
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
The purpose of the study was to assess the clinical effect of QAW039 in non-atopic asthmatics taking low dose Inhaled Corticosteroid (ICS) as background therapy.
- Trial name
- NCT01836471
- Testing
- QAW039, Fluticasone 250 mcg, Fluticasone 100 mcg
- Where
- 76 sites in United States, Belgium and 8 more
- Volunteers
- 345 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma
The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on high doses of ICS-LABA.
- Trial name
- NCT01928771
- Testing
- Benralizumab
- Where
- 275 sites in United States, Australia and 15 more
- Volunteers
- 2,681 people
- Sponsor
- AstraZeneca
Asthma
Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices
This study assessed the efficacy, safety, tolerability, and pharmacokinetics of two different formulations of indacaterol, one administered via the Concept1 device and one administered via the Simoon device.
- Trial name
- NCT01012739
- Testing
- Indacaterol 150 μg via the Concept1 dry-powder inhaler, Indacaterol 60 μg via the Simoon dry-powder inhaler, Indacaterol 120 μg via the Simoon dry-powder inhaler
- Where
- 4 sites in Germany, Netherlands and 1 more
- Volunteers
- 35 people
- Sponsor
- Novartis Pharmaceuticals
Smoking, Asthma
E-cigarettes for Harm Reduction in Adults With Asthma
Smoking is the main cause of preventable disease and death in the US and impacts respiratory illnesses including COPD and asthma.
- Conditions
- Smoking, Asthma, Electronic Cigarette Use, Cigarette Smoking
- Trial name
- SWAP (NCT05278065)
- Testing
- Nicotine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Brown University
Post-Amputation Pain, Phantom Limb Pain
Electrical Nerve Block for Amputation Pain
The purpose of the clinical trial is to learn whether electrical nerve block via the Altius System is a safe and effective treatment for patients with post-amputation pain.
- Conditions
- Post-Amputation Pain, Phantom Limb Pain, Residual Limb Pain, Stump Pain
- Trial name
- NCT02221934
- Testing
- Altius
- Where
- 22 sites in United States
- Volunteers
- 607 people
- Sponsor
- Neuros Medical, Inc.
Emphysema
Losartan Effects on Emphysema Progression
A randomized, parallel, placebo controlled trial to evaluate the effect of 100mg/day losartan on the progression of emphysema as measured by quantitative HRCT compared to placebo .
- Trial name
- LEEP (NCT02696564)
- Testing
- Losartan
- Where
- 28 sites in United States
- Volunteers
- 220 people
- Sponsor
- JHSPH Center for Clinical Trials
Chronic Obstructive Pulmonary Disease (COPD)
A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation
This study will assess the efficacy, safety and tolerability of indacaterol maleate/glycopyrronium bromide in patients with moderate to severe airflow limitation.
- Trial name
- NCT01712516
- Testing
- QVA149, QAB149, NVA237
- Where
- 95 sites in United States, Colombia and 7 more
- Volunteers
- 1,001 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study Of RV-39 In Patients Who Also Have Asthma
This study will last up to 9 weeks. Subjects will visit the clinic up to 14 times. Certain clinic visits will include a physical examination, lung function tests, inflammatory cell analysis from nasal secretions and/or sputum…
- Trial name
- NCT00503009
- Testing
- fluticasone propionate/salmeterol, fluticasone propionate
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Anemia, Kidney Failure
Dynepo Infrequent Dosing Study
The purpose of this study is to demonstrate non-inferiority of efficacy between twice weekly and once weekly dose schedule of Dynepo in previously erythropoietin (EPO)-naive patients, as measured by haemoglobin at week 24 and…
- Trial name
- NCT00450333
- Testing
- Dynepo (Epoetin delta), Dynepo
- Where
- 53 sites in Austria, Belgium and 5 more
- Volunteers
- 407 people
- Sponsor
- Shire
Asthma
Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium
The purpose of this trial was to demonstrate that the efficacy of two treatment arms of the fixed-dose combination product QVM149 was non-inferior to the efficacy of the free combination arm of salmeterol/ fluticasone+ tiotropium…
- Trial name
- ARGON (NCT03158311)
- Testing
- QVM149, Salmeterol/fluticasone plus tiotropium
- Where
- 163 sites in Argentina, Chile and 18 more
- Volunteers
- 1,426 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Tiotropium / Respimat One-Year Study
To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the Respimat inhaler in patients with COPD.
- Trial name
- NCT00168844
- Testing
- Tiotropium Inhalation Solution
- Where
- 72 sites in United States, Australia and 12 more
- Volunteers
- 983 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
PT003 MDI Dose Confirmation Study
The primary objective of this study is to demonstrate efficacy of PT003 MDI relative to its individual components (PT001 MDI and PT005 MDI) in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01349816
- Testing
- PT003, PT001, PT005
- Where
- 13 sites in United States
- Volunteers
- 185 people
- Sponsor
- Pearl Therapeutics, Inc.
Asthma, Panic Disorder
LUCHAR - Latinos Using Counseling for Help With Asthma and Anxiety Reduction
The research plan involves two aims: 1) Cultural adaptation of the Panic-Asthma Treatment and 2) a randomized, placebo-controlled pilot study.
- Trial name
- LUCHAR (NCT01583296)
- Testing
- Music Relaxation Therapy (MRT), CBT and HRVB
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Albert Einstein College of Medicine
Asthma
MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects
This is a multi-centre, open-label long term safety study of 100 milligrams (mg) mepolizumab administered subcutaneously (SC) in addition to standard of care in subjects who participated in the MEA112997 study.
- Trial name
- NCT01691859
- Testing
- Mepolizumab
- Where
- 64 sites in United States, Argentina and 11 more
- Volunteers
- 347 people
- Sponsor
- GlaxoSmithKline
Asthma
Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects
This study will investigate the effect of dosing paedeatric asthmatic subjects with GW642444, an orally inhaled long-acting agonist of the β2-adrenoceptor.
- Trial name
- NCT01453296
- Testing
- GW642444
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Asthma, Wheezing
A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children
This is a retrospective cohort study of children included in a large medical insurance claims database.
- Conditions
- Asthma, Wheezing, Immunosuppression
- Trial name
- NCT00626808
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 321,697 people
- Sponsor
- MedImmune LLC
Asthma, Perennial Allergic Rhinitis
Subcutaneous Immunotherapy for Mouse in Adults
This is an open label trial of mouse allergenic extract administered by subcutaneous injection in adults with asthma and mouse sensitivity.
- Trial name
- SCITMO (NCT02532179)
- Testing
- Mouse Allergenic Extract
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.